Survival associated with chronic obstructive pulmonary disease among SEER-Medicare beneficiaries with non-small-cell lung cancer
Survival associated with chronic obstructive pulmonary disease among SEER-Medicare beneficiaries with non-small-cell lung cancer
复制标题
DOI：
10.2147/copd.s185837
复制
发表时间：
2019-01-01
影响因子：
2.8
通讯作者：
Howden, Reuben
中科院分区：
文献类型：
--
作者：
Shah, Shweta;Blanchette, Christopher M.;Howden, Reuben
目的：我们调查了既存COPD及其亚型慢性支气管炎和肺气肿对诊断为非小细胞肺癌（NSCLC）的医疗保险登记者总生存率的影响。方法：使用SEER-Medicare数据，我们包括患者>=在2006年至2010年期间被诊断患有任何疾病阶段的NSCLC，并在2010年之前的12个月内连续参加Medicare A部分和B部分诊断.使用ICD-9编码识别NSCLC患者中既存COPD。采用Kaplan-Meier法和对数秩检验分析COPD状态和COPD亚型的总生存期。多变量考克斯比例风险模型被用来评估癌症诊断后的死亡风险。其中，22，497例（33.60%）患者在NSCLC诊断前记录了COPD。对于各期NSCLC，COPD组的中位生存期均短于非COPD组（I期：692天vs 1，130天，P
Objective: We investigated the impact of preexisting COPD and its subtypes, chronic bronchitis and emphysema, on overall survival among Medicare enrollees diagnosed with non-small-cell lung cancer (NSCLC).Methods: Using SEER-Medicare data, we included patients >= 66 years of age diagnosed with NSCLC at any disease stage between 2006 and 2010 and continuously enrolled in Medicare Parts A and B in the 12 months prior to diagnosis. Preexisting COPD in patients with NSCLC were identified using ICD-9 codes. Kaplan-Meier method and log-rank tests were used to examine overall survival by COPD status and COPD subtype. Multivariable Cox proportional hazards models were fit to assess the risk of death after cancer diagnosis.Results: We identified 66,963 lung cancer patients. Of these, 22,497 (33.60%) had documented COPD before NSCLC diagnosis. For each stage of NSCLC, median survival was shorter in the COPD compared to the non-COPD group (Stage I: 692 days vs 1,130 days, P